On 21 July 2026, the Central Drugs Standard Control Organisation (CDSCO) — India's national drug regulator — granted marketing authorisation for a Dengue Tetravalent Vaccine (Live, Attenuated), marketed as Qdenga (TAK-003), for the prevention of dengue in individuals aged 4–60 years. It is India's first-ever approved dengue vaccine. For an NDA aspirant, this is a rich science-and-health topic: it opens up dengue and how it spreads, the biology of viruses and vaccines, and India's drug-regulation system — all high-yield General Science.
The news in one frame
The essentials:
- What: CDSCO approved India's first dengue vaccine — Qdenga (TAK-003), a live, attenuated tetravalent vaccine.
- For whom: individuals aged 4–60 years.
- Who makes it: Takeda (Germany); it is WHO-prequalified and already approved in 42 countries.
- Why it matters: dengue is a major public-health burden in India; a vaccine strengthens prevention.
What is dengue?
Start with the disease. Dengue is a viral disease caused by the dengue virus (DENV) and spread by the bite of an infected Aedes mosquito (mainly Aedes aegypti). Key facts:
- The Aedes mosquito is a day-biter and breeds in clean, stagnant water (coolers, tyres, flowerpots, tanks) — unlike the malaria mosquito (Anopheles), which prefers dirty water and bites at night.
- Symptoms include high fever, severe headache, pain behind the eyes, joint and muscle pain ("breakbone fever") and rash; severe cases cause bleeding and shock (dengue haemorrhagic fever).
- There are four serotypes — DENV-1, 2, 3 and 4. Recovery from one gives lifelong immunity to that serotype only; a later infection by a different serotype raises the risk of severe dengue — which makes a vaccine covering all four valuable.
The same Aedes mosquito also spreads chikungunya, Zika and yellow fever. This applied biology is exactly what the NDA general-knowledge and biology notes cover.
How a vaccine works
Now the immunology — a favourite NDA science area. A vaccine trains the body's immune system to recognise and fight a germ without causing the disease. It contains a harmless form of the pathogen (an antigen), which prompts the body to make antibodies and memory cells — so if the real germ attacks later, the body responds fast. The main types of vaccine to know:
- Live-attenuated — a weakened live germ (e.g., BCG, MMR, oral polio, and this dengue vaccine). Strong, lasting immunity, usually few doses.
- Inactivated/killed — the germ is dead (e.g., injectable polio, rabies).
- Subunit/toxoid — only a part of the germ or its inactivated toxin (e.g., tetanus toxoid, Hepatitis B).
- mRNA / viral-vector — newer types (e.g., some Covid-19 vaccines).
Qdenga is a live-attenuated, tetravalent vaccine — "tetravalent" meaning it protects against all four dengue serotypes at once. This is central to understanding the news. These themes recur in the NDA daily current affairs.
Immunity and herd immunity
Round out the immunology with the concepts the exam pairs with vaccines:
- Active immunity — the body makes its own antibodies (from infection or vaccination); long-lasting.
- Passive immunity — ready-made antibodies are given (e.g., from mother to baby, or an anti-venom/anti-serum); quick but short-lived.
- Herd immunity — when enough of a population is immune, the germ can't spread easily, protecting even the unvaccinated.
- A vaccine is prevention, not a cure — it works best alongside vector control (killing mosquitoes) and public awareness.
India's drug-regulation system
Place the regulator clearly — examinable in itself:
- CDSCO (Central Drugs Standard Control Organisation) is India's national drug regulator, under the Ministry of Health & Family Welfare.
- It is headed by the Drugs Controller General of India (DCGI), and approves new drugs, vaccines and clinical trials under the Drugs and Cosmetics Act, 1940.
- Vaccine safety and quality are checked before marketing authorisation is granted — as done here after "comprehensive scientific evaluation."
- India is a global vaccine manufacturing hub ("pharmacy of the world"), home to major producers like the Serum Institute of India.
Why it matters
For the SSB and the bigger picture:
- Public health: dengue causes large seasonal outbreaks (especially in the monsoon); a vaccine can cut severe cases and deaths.
- Prevention over cure: with no specific antiviral drug for dengue, prevention (vaccine + mosquito control) is crucial.
- Self-reliance: approval and eventual domestic production advance India's health security and Aatmanirbhar goals.
🔑 Revision block
The approval. 21 July 2026 — CDSCO grants marketing authorisation to a Dengue Tetravalent Vaccine (Live, Attenuated), sold as Qdenga (TAK-003) by Takeda (Germany), ages 4–60 — India's first, already WHO-prequalified and cleared in 42 countries.
The disease. Viral, from the dengue virus (DENV) → high fever, severe headache, pain behind the eyes, joint and muscle pain ("breakbone fever"), rash → severe cases bleed and shock (dengue haemorrhagic fever). No specific antiviral exists.
The vector trap. Aedes aegypti: day-biter, breeds in clean, stagnant water — coolers, tyres, flowerpots, tanks. Malaria's Anopheles is the opposite: dirty water, night. The same Aedes carries chikungunya, Zika, yellow fever.
Why "tetravalent" is the point. DENV-1, 2, 3, 4 → one infection gives lifelong immunity to that serotype only → a later, different serotype raises the risk of severe dengue → cover all four.
Vaccine types. Live-attenuated (BCG, MMR, oral polio, this one) · inactivated/killed (injectable polio, rabies) · subunit/toxoid (tetanus toxoid, Hepatitis B) · mRNA / viral-vector (some Covid-19 vaccines).
Immunity words. Active = own antibodies and memory cells, long-lasting · passive = ready-made antibodies (mother to baby, anti-venom), quick but short-lived · herd immunity = enough immune that the germ cannot spread.
The regulator. CDSCO (Central Drugs Standard Control Organisation), under the Ministry of Health and Family Welfare, headed by the Drugs Controller General of India (DCGI), clearing drugs, vaccines and trials under the Drugs and Cosmetics Act, 1940 — in the "pharmacy of the world", home of the Serum Institute of India.
🎯 Practice MCQs
Q1. Dengue is caused by a: (a) virus (b) bacterium (c) fungus (d) protozoan → (a) — the dengue virus (DENV).
Q2. Dengue is transmitted by which mosquito? (a) Aedes aegypti (b) Anopheles (c) Culex (d) housefly → (a) — the Aedes mosquito.
Q3. The Aedes mosquito typically breeds in: (a) clean, stagnant water (b) dirty drains only (c) fast rivers (d) the sea → (a) — clean, stagnant water.
Q4. How many serotypes of the dengue virus are there? (a) four (b) two (c) one (d) ten → (a) — four (DENV-1 to DENV-4).
Q5. India's first dengue vaccine, Qdenga, is a: (a) live-attenuated tetravalent vaccine (b) killed bacterial vaccine (c) antibiotic (d) painkiller → (a) — a live-attenuated, tetravalent vaccine.
Q6. "Tetravalent" means the vaccine protects against: (a) all four dengue serotypes (b) four diseases (c) four age groups (d) four doses → (a) — all four DENV serotypes.
Q7. India's national drug regulator is: (a) CDSCO (b) ICMR (c) AIIMS (d) FSSAI → (a) — the Central Drugs Standard Control Organisation.
Q8. CDSCO is headed by the: (a) DCGI (b) DGCA (c) RBI Governor (d) Cabinet Secretary → (a) — the Drugs Controller General of India.
Q9. A vaccine works by stimulating the body to produce: (a) antibodies and memory cells (b) red blood cells only (c) insulin (d) hormones → (a) — antibodies (and immune memory).
Q10. Which is a live-attenuated vaccine? (a) BCG / MMR (b) tetanus toxoid (c) rabies (killed) (d) Hepatitis B (subunit) → (a) — BCG/MMR (weakened live germs).
Q11. "Active immunity" means the body: (a) makes its own antibodies (b) is given ready-made antibodies (c) has no immunity (d) uses antibiotics → (a) — produces its own antibodies (long-lasting).
Q12. "Passive immunity" is: (a) ready-made antibodies given from outside (b) lifelong (c) from a vaccine (d) never used → (a) — externally supplied antibodies (short-lived).
Q13. When enough people are immune so a disease can't spread, it is called: (a) herd immunity (b) passive immunity (c) autoimmunity (d) allergy → (a) — herd immunity.
Q14. Recovery from one dengue serotype gives lifelong immunity to: (a) only that serotype (b) all four (c) none (d) malaria too → (a) — only that serotype.
Q15. Which other disease is also spread by the Aedes mosquito? (a) chikungunya (b) tuberculosis (c) typhoid (d) cholera → (a) — chikungunya (also Zika, yellow fever).
Q16. CDSCO approves drugs and vaccines under the: (a) Drugs and Cosmetics Act, 1940 (b) IPC (c) Factories Act (d) Consumer Protection Act → (a) — the Drugs and Cosmetics Act, 1940.
📋 How this gets asked (PYQ pattern)
Diseases and immunity are a high-frequency NDA science set. The reliable framings are dengue's cause/vector (virus, Aedes), the four serotypes, vaccine types (live-attenuated etc.), and active vs passive/herd immunity. A common trap swaps the dengue vector (Aedes) with the malaria vector (Anopheles) or calls dengue bacterial. The fresh 2026 hook is India's first dengue vaccine (Qdenga, CDSCO) — ideal for "which vector / which type / which regulator" items. We reference the pattern, not any exact past question.
Preparing for the NDA? Diseases, immunity and vaccines are high-yield General Science and good SSB talking points on public health. Follow our daily NDA current affairs and train with serving-officer faculty in the upcoming Cavalier courses in Delhi.
✍️ Written by Col D.N. Sharma — Science & general-studies faculty at The Cavalier. Reviewed by the Cavalier Faculty Desk. The Cavalier, founded by ex-Army officers, has trained NDA/CDS/SSB aspirants since 2001 (Facebook · YouTube).
Source: PIB / CDSCO, Ministry of Health & Family Welfare, 21 July 2026. Facts cross-verified with independent sources.